

1 **Short Title: VEE complex, MADV and EEEV**

2

3 **Venezuelan equine encephalitis complex, Madariaga and Eastern equine**
4 **encephalitis viruses genome detection in human and mosquito populations**

5

6 Jean-Paul Carrera^{1,2,3,4#}, Dimelza Araúz³, Alejandra Rojas⁵, Fátima Cardozo⁵, Victoria

7 Stittleburg⁶, Ingra Morales Claro^{7,9}, Josefrancisco Galue^{3,4}, Carlos Lezcano-Coba^{3,4}, Filipe

8 Romero Rebello Moreira^{8,9}, Luis Felipe-Rivera^{3,4}, Maria Chen-Germán³, Brechla Moreno³, Zeuz

9 Capitan-Barrios^{3,4,10}, Sandra López-Vérges³, Juan Miguel Pascale¹¹, Ester C. Sabino⁷, Anayansi

10 Valderrama^{4,12}, Kathryn A. Hanley¹³, Christl A. Donnelly^{2,9,14}, Nikos Vasilakis^{+15, 16,17,18,19,20,}

11 Nuno R. Faria^{+1,7,9}, Jesse J. Waggoner^{+6,21,#}

12

13 1. Department of Biology, University of Oxford, Oxford, United Kingdom

14 2. Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford,
15 Oxford, United Kingdom

16 3. Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of
17 Health Studies, Panama City, Panama

18 4. Viral Emerging Disease Dynamics group, Gorgas Memorial Institute of Health Studies,
19 Panama City, Panama

20 5. Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
21 Departamento de Producción, Paraguay

22 6. Emory University, Department of Medicine, Division of Infectious Diseases, Atlanta,
23 Georgia, USA

- 24 7. Instituto de Medicina Tropical, Faculdade de Medicina da Universidade de São Paulo,
25 São Paulo, Brazil
- 26 8. Departamento de Genética, Universidade Federal do Rio de Janeiro, Brazil
- 27 9. MRC Centre for Global Infectious Disease Analysis (MRC-GIDA), Department of
28 Infectious Disease Epidemiology, Imperial College London, London United Kingdom
- 29 10. Departamento de Microbiología y Parasitología, Facultad de Ciencias Naturales, Exactas
30 y Tecnología, Universidad de Panamá, Ciudad de Panamá, Panamá
- 31 11. Clinical of Tropical Diseases and Research Unit, Gorgas Memorial Institute of Health
32 Studies, Panama City, Panama
- 33 12. Department of Medical Entomology, Gorgas Memorial Institute of Health Studies,
34 Panama City, Panama
- 35 13. Department of Biology, New Mexico State University, Las Cruces, New Mexico, USA
- 36 14. Department of Statistics, University of Oxford, Oxford, United Kingdom
- 37 15. Department of Pathology, The University of Texas Medical Branch, Galveston, Texas,
38 USA
- 39 16. Department of Preventive Medicine and Population Health, The University of Texas
40 Medical Branch, Galveston, Texas, USA.
- 41 17. Center for Biodefense and Emerging Infectious Diseases, The University of Texas
42 Medical Branch, Galveston, Texas, USA.
- 43 18. Center for Vector-Borne and Zoonotic Diseases, The University of Texas Medical
44 Branch, Galveston, Texas, USA.
- 45 19. Center for Tropical Diseases, The University of Texas Medical Branch, Galveston,
46 Texas, USA.

47 20. Institute for Human Infection and Immunity, The University of Texas Medical Branch,
48 Galveston, Texas, USA.

49 21. Rollins School of Public Health, Department of Global Health, Atlanta, Georgia, USA

50

51 #Address correspondence to: Jean-Paul Carrera, Peter Medawar Building for Pathogen Research,

52 Oxford, UK, OX1 3SY. Email: jean.carrera@biology.ox.ac.uk; jpcarrera@gorgas.gob.pa or

53 Jesse J. Waggoner, 1760 Haygood Drive NE, Room E-169, Bay E-1, Atlanta, GA, USA, 30322.

54 Email: jjwaggo@emory.edu; Telephone: +1 (404) 712-2360.

55

56 +joint senior authors

57

58 Word Count: Abstract, 231; Manuscript, 4509

59 Inserts: Tables 4, Figure 4

60

61 **Abstract**

62 Eastern equine encephalitis virus (EEEV), Madariaga virus (MADV) and Venezuelan equine
63 encephalitis virus complex (VEEV) are New World mosquito-borne alphaviruses and cause
64 severe neurological disease in human and equine hosts. However, their detection during the acute
65 phase is complicated by non-specific clinical manifestations and lack of available diagnostic
66 tools. To develop and clinically evaluate rRT-PCRs for VEEV complex, MADV and EEEV,
67 primers and probes were designed from publicly available whole-genome sequences. The rRT-
68 PCRs were validated using 15 retrospective serum samples from febrile patients collected during
69 the 2015 and 2017 alphavirus outbreaks in Panama. In addition, the protocol was validated with

70 150 mosquito pools from 2015, and with 118 samples from prospective disease surveillance from
71 2021 and 2022. The rRT-PCRs detected VEEV complex RNA in 10 samples (66.7%) from the
72 2015 and 2017 outbreaks, and in one of these ten samples, both VEEV complex and MADV
73 RNAs were detected. Additionally, VEEV complex RNA was detected in 5 suspected dengue
74 from prospective disease surveillance. The rRT-PCR assays detected VEEV complex RNA in 3
75 from *Culex (Melanoconion) vomerifer* pools, 2 of which yielded VEEV isolates. Untargeted
76 sequencing and phylogenetic analysis identified VEEV ID subtype in
77 seven VEEV complex RNA positive sample. The VEEV complex, MADV and EEEV rRT-
78 PCRs provide accurate detection while yielding significant benefits over currently available
79 molecular methods. Our results suggest that 11.9% of suspected dengue cases in Panama are
80 VEEV infections.

81
82 **Keywords:** Venezuelan equine encephalitis, Madariaga virus, Eastern equine encephalitis virus,
83 alphavirus, rRT-PCR.

84

85 **Introduction**

86 New World alphaviruses (*Togaviridae*, genus *Alphavirus*) comprise a diverse group of mosquito-
87 borne viruses that can cause severe disease in humans, including the Venezuelan equine
88 encephalitis virus complex (VEEV complex), Madariaga virus (MADV), and eastern equine
89 encephalitis virus (EEEV)(1). These have single-stranded 11.7kb RNA genomes that encode four
90 non-structural proteins (nsP1 to nsP4) and five structural proteins (capsid, E1, E2, E3 and 6K) (1,
91 2). VEEV complex, MADV and EEEV persist in sylvatic-enzootic cycles throughout the

92 Americas and are transmitted to humans by *Aedes spp.*, *Psorophora spp.* and *Culex spp.*
93 mosquitoes (2, 3).

94
95 Serologic and molecular evidence of VEEV complex infections have been identified throughout
96 tropical regions of Central and South America, suggesting VEEV complex infections may be
97 relatively common but remain largely underdiagnosed(2) . There is a high genetic variability
98 within the VEEV complex, with at least 14 different viral subtypes identified to date (2). VEEV
99 complex subtypes have been associated with large epizootic outbreaks involving equids and
100 humans (VEEV subtypes IAB and IC)(1, 2). Although most infections in humans are
101 asymptomatic or subclinical, patients may develop acute febrile illness with headache, myalgias,
102 arthralgias, nausea, and vomiting (4, 5), which may progress to severe disease including
103 encephalitis and the development of long-term neurologic sequelae(5, 6).

104
105 MADV, previously classified as South American EEEV, is an emerging virus that was first
106 associated with large outbreaks in 2010 in the Darién province of Panamá (5), where VEEV
107 subtype ID has also been detected(7). Before the 2010 outbreak in Panama, MADV was mostly
108 associated with equine disease and only a few human infections had been detected in Trinidad
109 and Tobago and Brazil(8, 9). This contrasts with the epidemiological profile of the North
110 American EEEV, which is associated with severe and fatal human cases(3). Diagnostic tools are
111 not widely available for MADV, and its prevalence outside of the Darién province in Panama
112 remains poorly characterized(10). Geographic expansion of the Panamanian MADV strain into
113 Northeast Brazil and Haiti has been reported recently, highlighting the potential of MADV to
114 invade new areas (11, 12).

115 Accurate detection of VEEV complex, MADV and EEEV infections in the acute phase is
116 complicated by their non-specific clinical manifestations and lack of widely available diagnostic
117 tools. Antigen-based methods are currently unavailable, and although serology can confirm the
118 diagnosis, this requires paired acute and convalescent samples (1, 5). Current molecular tests
119 lack optimal performance characteristics necessary for routine diagnostic testing (13–19).
120 Molecular assay designs have been complicated by the genetic variability of the VEEV complex
121 viruses(2). VEEV complex infections are often misdiagnosed as dengue virus, due to
122 overlapping clinical symptoms during the acute phase (2), and the recent classification of MADV
123 as a separate virus species and human pathogen further complicates the clinical diagnosis of
124 both(3). Common molecular tests for the VEEV complex employ pan-alphavirus primers to
125 amplify a region of 400-500 nucleotides region of the genome with subsequent identification of
126 the viral complex or species by sequencing or nested polymerase chain reaction (PCR)(5, 13, 14,
127 16, 18–20). Such methods are laborious and increase opportunities for laboratory contamination.
128 In addition, pan-alphavirus primers and conventional reverse transcription-polymerase chain
129 reaction (RT-PCR) chemistry may be less sensitive than real-time RT-PCR (rRT-PCR).
130 Moreover, few rRT-PCR methods have been reported in the literature to date to detect and
131 differentiate VEEV complex and MADV (21).

132
133 The primary objective of the current study was to design sensitive rRT-PCRs diagnosis assay for
134 the VEEV complex and MADV. As a secondary objective, a duplex MADV/EEEV rRT-PCR
135 was developed to differentiate these two pathogens. The two assays, for VEEV complex and
136 MADV/EEEV detection, were evaluated in a set of clinical samples from an alphavirus outbreak
137 in Panamá and prospective disease surveillance. Finally, we characterized viral species, subtype

138 and genotype from selected rRT-PCR, positive samples from humans and mosquitoes collected
139 during the 2015 and 2022 alphavirus outbreaks in Panama using metagenomic sequencing
140 approach.

141

142 **Materials and Methods**

143 **Ethics statement**

144 The use of human samples used for protocol validation was approved by the Panamanian
145 Ministry of Health (protocol number 2077), Gorgas's Institutional Review Board (IRB)
146 (protocol: 335/CBI/ICGES/21), Emory University IRB (IRB00097089), and the Ethics
147 Committee of the Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de
148 Asunción (P06/2017). Prospective disease surveillance was approved by the Gorgas's IRB
149 (protocol:073/CBI/ICGES/21).

150

151 **Data availability**

152 All the data used for human and mosquito validation are contained within the manuscript.
153 Accessions numbers of newly derived genomes are XXX. Accessions numbers and strains
154 information of sequences used for primer design are shown in Supplementary Appendix.

155

156 **VEEV complex, EEEV and MADV rRT-PCR design**

157 Separate alignments were prepared for the VEEV complex, EEEV and MADV using all publicly
158 available complete genome sequences from the NCBI GenBank (22) and aligned with MegAlign
159 software (DNASTAR, Madison, WI). The VEEV complex alignment included all complete
160 genomes from the following viruses: Cabassou, Everglades, Mosso das Pedras, Mucambo,

161 Pixuna, Rio Negro, Tonate, and VEEV subtypes (IAB, IC, ID, and IE). The VEEV complex
162 alignments were compiled in 2016 (n=121 sequences); a similar alignment for MADV was
163 compiled in 2019 (n=32). Primers and probes were designed with Primer3 software
164 (primer3.ut.ee) such that each oligonucleotide contained ≤ 1 degenerate base and matched $\geq 95\%$
165 of available sequences for a given virus. In silico primer/probe specificity was checked by
166 aligning sequences in BLAST (blast.ncbi.nlm.nih.gov) against (i) all available sequences and (ii)
167 only alphavirus sequences while excluding the VEEV complex or MADV, respectively. Due to
168 the similarity between MADV primers and EEEV sequences, all available EEEV complete
169 genome sequences (n=441) were aligned and separate MADV and EEEV probes were designed
170 for an rRT-PCR duplex assay. Alignments for each virus were repeated with all sequences
171 available in September 2021 to confirm primer and probe sequences in contemporary strains.

172

173 **rRT-PCR assay performance and optimization**

174 rRT-PCRs were performed in 25 μ L reactions using the SuperScript III Platinum One-Step
175 Quantitative RT-PCR Kit (Thermo Fisher, Waltham, MA) with 5 μ L of the nucleic acid template.
176 The analytical evaluation was performed on a Rotor-Gene Q instrument (Qiagen, Germantown,
177 MD), and the validation with serum and mosquito pool samples was performed on an ABI7500
178 (Thermo Fisher). Cycling conditions were consistent with previous laboratory protocols: 52 °C \times
179 15 min, 94 °C \times 2 min, and 45 cycles of 94 °C \times 15 s, 55 °C \times 40 s (acquired in all channels),
180 and 68 °C \times 20 s (1-4). Primer and probe sets were evaluated in singleplex reactions containing
181 200nM of each oligonucleotide and genomic RNA or quantified ssDNA containing the target
182 region. Primer/probe sets were selected to generate the most sensitive detection based on cycle

183 threshold (Ct) values, with preserved specificity. Primer and probe concentrations in the final
184 reaction were then adjusted between 100nM and 400nM to optimize assay sensitivity.
185 Primers were obtained from Integrated DNA Technologies (IDT, Coralville, Iowa); probes were
186 obtained from Biosearch Technologies (Hoddesdon, United Kingdom). VEEV subtype IC and
187 EEEV genomic RNAs were purchased from Vircell Microbiologists (Granada, Spain).
188 Quantified ssDNA containing the assay target region (IDT, Coralville, Iowa) was used for all
189 viruses to quantify analytical performance. For ssDNA synthesis, target region sequences were
190 selected from specific strains of VEE subtype IAB (Accession number KC344505.2) and
191 subtype IV (Pixuna virus, Accession number NC_038673.1), MADV (Accession numbers
192 MH359233.1 and KJ469626.1), and EEEV (Accession number KX029319.1).

193

194 **Analytical evaluation**

195 The linear range of the assay was determined by testing synthesized targets from each reference
196 strain in quadruplicate at 8.0, 6.0, 4.0, 2.0, and 1.0 log₁₀ copies/μL. The linear range was defined
197 as the range of concentrations at which 1) all replicates were detected and 2) the linear regression
198 of Ct values (y, dependent variable) versus log₁₀ copies/ μL (x, independent variable) generated
199 an R² ≥ 0.99. For the VEEV complex, the lower limit 95% detection (95% LLOD) was
200 determined by testing 10 replicates of 2-fold serial dilutions from 200 to 25 copies/μl. For
201 MADV and EEEV, 95% LLOD was calculated directly from the linear range. Assay exclusivity
202 was evaluated by testing genomic RNA from the following viruses (strain in parentheses, if
203 designated): Rift Valley fever (h85/09); Zika (ZIKV; MR766); dengue virus serotype 1 (DENV1,
204 Hawaii 1944), DENV2 (NGC), DENV3 (Sleman/78), and DENV4 (H241); chikungunya virus
205 (CHIKVR80422); Mayaro virus (MAYV; ARV 0565, INHRR 11a-10); yellow fever virus

206 (YFV; 17D and Asibi strains); West Nile virus (WNV; NAL); St. Louis encephalitis virus
207 (SLEV; GML 902612, CorAn 9275); tick-borne encephalitis virus (TBEV; Japanese encephalitis
208 virus (JEV); Semliki Forest virus (SFV); Ross River virus (RRV); Getah virus (GETV); Barmah
209 Forest virus (BFV); and Una virus (UNAV) (5). Specificity was also evaluated by testing 56
210 serum samples from locations without known transmission of VEEV or MADV. These included
211 8 samples collected from patients in Georgia, USA, without known travel history, and 48
212 samples from individuals with an acute febrile illness in Asunción, Paraguay. The latter samples
213 have been described in detail elsewhere (23). Total nucleic acids were extracted from 200 μ L of
214 serum on an EMAG instrument (BioMérieux, Durham, NC), eluted in 50 μ L and run in the
215 VEEV complex and MADV/EEEV rRT-PCRs.

216

217 **Statistics**

218 Linear regression fitting and linear range calculations, including R^2 of the best-fit line were
219 performed in Excel (Microsoft, Redmond, WA). Concentrations and replicates in the linear range
220 study that did not yield Ct values were not included in the linear regression analysis. Probit
221 analyses were performed using MedCalc, v20.013 (MedCalc Software, Belgium).

222

223 **Protocol validation with acute human samples**

224 Acute human samples used in the protocol validation were collected in communities of Darien,
225 the eastern most province in Panama, during three alphavirus outbreaks in 2015, 2017. Cases
226 identified in 2015 and 2017 were detected in the communities of Metetí, Cemaco, Tucutí,
227 Yaviza, Nicanor, La Palma and El Real de Santa María (Figure 1A). The Darien province

228 borders Colombia and encompasses the Darien Gap, and the Darien National Park, a UNESCO-
229 designated World Heritage Site(24).

230

231 **Patient recruitment in 2015 and 2017**

232 Febrile patients were identified during an enhanced surveillance program by our outbreak
233 response team using house-by-house visits during the 2015 and 2017 outbreaks. Blood samples
234 were drawn from patients that met the case definition during the outbreak investigation. The case
235 definition of a suspected case included fever and headache, while a probable case was defined as
236 a suspected case plus somnolence, lethargy, or convulsions. Blood samples were centrifuged in
237 the field, and serum was stored in liquid nitrogen for transportation to the Gorgas Memorial
238 Institute of Health Studies in Panama City.

239

240 **Prospective acute disease surveillance in 2021 and 2022**

241 In 2021 an effort for surveillance of emerging pathogens was established in Panama as part of
242 the USA-National Institute of Allergy and Infectious Diseases (NIAID), Centers for Research in
243 Emerging Infectious Diseases Network initiative. The **C**oordinating **R**esearch on **E**merging
244 **A**rboviral **T**hreats **E**ncompassing the **N**eotropics (CREATE-NEO) in Panama undertakes acute
245 febrile surveillance across ten Health Centers in Panama and Darien Provinces (Figure 1 B)
246 (<https://www.utmb.edu/createneo/home/create-neo-home>). Cases, with malaria, human
247 immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis (HCV), and >5 and <75 years
248 old, presenting with no more than 7 days with rash, and at least one of the following symptoms:
249 fever, myalgia, arthralgia, periarticular edema, and conjunctivitis were recruited, evaluated and

250 interviewed, to obtain clinical, and demographics characteristics and ethic consent at each health
251 center.

252

253 **Laboratory testing for acute disease surveillance**

254 Acute samples (0-5 days) were first screened against DENV, CHIKV and ZIKV virus using rRT-
255 PCR as described previously (25), followed by testing with the newly designed MADV/VEEV
256 rRT-PCR.

257

258 **Mosquito collection**

259 Mosquito collections were performed in a forested section of 100 x 100 meters within El Real de
260 Santa María (Figure 1 A). Acute VEEV cases were identified during the 2015 outbreak response
261 in El Real de Santa María. Mosquito collections were undertaken with CDC light traps and
262 performed over a period of 12 hours, from 6:00 pm to 6:00 am at a height of 1.5 m above ground
263 level. Traps (BioQuip Products, Rancho Dominguez, CA) were baited with octanol and CO₂ for
264 the encephalitis vector survey. The following day, mosquitoes were collected in the field and
265 transported to the base camp where they were anesthetized, identified to the species level using
266 taxonomic keys (26), and placed in cryovials for storage in liquid nitrogen. Mosquitos were
267 grouped at the species level and a maximum of 20 individuals were used to produce mosquito
268 pools for rRT-PCR, serology, and isolation.

269

270 **Alphavirus serology of clinical samples**

271 All human serum samples were tested in duplicate for IgM antibodies to MADV and VEEV
272 antigen using an enzyme-linked immunosorbent assay (ELISA) and confirmed by a plaque-

273 reduction neutralization test (PRNT). For the ELISA, sucrose-acetone antigens were prepared
274 from MADV- (prepared by Dr. Robert Shope at the Yale Arbovirus Research Unit in August
275 1989) and VEEV- (strain TC-83) infected mouse brain. For the PRNT, we used chimeric Sindbis
276 virus SINV/MADV (derived from Brazilian MADV strain BeAn436087 and shown to be an
277 accurate surrogate for MADV in these assays (27) and TC83, an attenuated vaccine strain of
278 VEEV closely related to subtype ID strains that circulate in Panama (7). The neutralizing
279 antibody titer was determined as the reciprocal of the highest dilution that reduced plaque count
280 by 80% (PRNT₈₀).

281

282 **Viral isolation from mosquito pools**

283 Mosquito pool homogenates were prepared with 20 – 50 mosquitoes in 2 mL of minimum
284 essential medium supplemented with penicillin and streptomycin, and 20% fetal bovine serum,
285 homogenized using a Tissue Lyser (Qiagen, Hidden, Germany), and centrifuged at 12000 rpm
286 for 10 mins. A total of 200 µL of serum or mosquito homogenate was inoculated in each of two
287 12.5-cm² flasks of Vero cells. Samples were passed twice and monitored for cytopathic effect
288 (CPE).

289

290 **Generic alphavirus RT-PCR for human and mosquito samples**

291 Viral RNA was extracted from human sera and mosquito pool homogenates using QIAamp RNA
292 viral extraction kit (Qiagen, Valencia, CA). Viral RNA from mosquitoes was also extracted
293 using the Macherey-Nagel extraction kit (Düren, Germany). Sera and mosquito homogenates
294 were tested in 25µL reactions for alphaviruses using a universal alphavirus RT-PCR, as
295 previously described (19).

296 **Viral metagenomic sequencing**

297 To confirm virus species, subtype and genotype, we sequenced seven selected VEEV complex
298 rRT-PCR positive mosquito and human samples from 2015 and 2022 using SMART-9N
299 metagenomic sequencing as previously described (28). In brief, viral RNA was treated with
300 TURBO DNase (Thermo Fisher Scientific, USA) and concentrated with Zymo RNA clean &
301 concentrator-5 (Zymo Research, USA) following protocol instructions. cDNA synthesis and
302 PCR was performed as described (28). Fifty ng of the quantified PCR products were pooled
303 using EXP-NBD104 (1-12) and EXP-NBD114 (13-24) Native Barcoding Kits (ONT, UK).
304 Sequencing libraries were generated using the SQK-LSK109 kit (ONT, UK) and loaded onto
305 FLO-MIN106 flow cells on the GridION device (ONT, UK). Sequencing base-calling and
306 demultiplexing was performed by MinKNOW with the standard 48-hour run script (ONT, UK).
307 Demultiplexed FASTQ files were aligned and mapped to the VEEV reference genome (GenBank
308 accession no. NC_001449.1) using minimap2 version 2.28. (29) and converted to sorted BAM
309 file using SaMtool(30). NanoStat version 1.1.2.4,(31) and Tablet (32) were used to compute
310 genomic statistics. Variants were detected with medaka_variants and consensus sequences were
311 built with margining_medaka_consensus (ONT, UK). Genomic regions with <20x coverage were
312 masked.

313

314 **VEEV Phylogenetic analysis**

315 All available VEEV genome sequences, in GenBank, representing all antigenic complex were
316 selected to construct the alignment, duplicated sequences, partial sequences and overlapping
317 sequences were removed. Finally, the novel complete or near complete VEEV genome
318 sequences (n=7) were aligned with 132 representative VEEV genomes retrieved from NCBI

319 GenBank using MAFFT version 7 (33). Selection of the best-fitting nucleotide substitution
320 model and maximum likelihood phylogenetic reconstruction were performed with IQ-Tree
321 v2.2.0.3(34). Statistical robustness of the tree topology was assessed with 1,000 ultrafast
322 bootstrap replicates.

323

324 **Results**

325 **rRT-PCR analytical evaluation**

326 Primers and probes for the VEE complex singleplex and MADV/EEEV duplex rRT-PCRs are
327 shown in Table 1 along with the optimized final reaction concentrations. The linear range for
328 each assay extended from 2.0 to 8.0 log₁₀ copies/μL (Figure 2A-D). For the VEEV complex
329 assay, the linear range was evaluated with ssDNA for subtypes IAB and IV and RNA from
330 subtype IC (2.0 to 5.0 log₁₀ copies/μL; Figure 1A-B). The 95% LLODs, expressed in copies/μL,
331 were: VEEV subtype IAB, 120; VEE subtype IV, 110; MADV, 19; EEEV, 19. Assay exclusivity
332 was evaluated by testing genomic RNA from VEEV subtype IC, EEEV, and a set of arboviruses,
333 including flavi-, bunya-, and alphaviruses on a single run of the VEEV complex and
334 MADV/EEEV rRT-PCRs. VEEV complex and EEEV only yielded signals in the respective
335 assays for these viruses. None of the other tested viruses generated signal in either assay. In
336 addition, none of the 56 serum samples from Georgia, USA, or Asunción, Paraguay, tested
337 positive in either assay.

338

339 **Validation with clinical samples**

340 A total of 15 febrile patients from 2015 and 2017 alphavirus outbreaks that met the suspected or
341 probable case definition were used to validate the new molecular assays. Previously, a total of

342 eleven (11/15) acute sera samples collected during the in 2015 and 2017 alphavirus outbreaks
343 had tested positive using a generic alphavirus RT-PCR and were confirmed later by sequencing
344 as VEEV-ID infections (17). In 2021, a second round of generic alphavirus RT-PCR using the
345 same set of primers was run on these 15 stored samples, and all of them tested negative. Notably,
346 using the newly designed rRT-PCR, we were able to detect 10 VEEV complex RNA positive
347 samples (Ct range: 27 – 38), including two samples that had tested negative at the initial
348 screening in 2017 (Table 2). Three of the VEEV complex rRT-PCR-positive samples were also
349 anti-VEEV IgG and IgM positive, with only 0, 2, and 3 days since the onset of symptoms,
350 respectively (Table 2). One sample was rRT-PCR positive for both VEEV and MADV viruses.
351

352 **Prospective disease surveillance**

353 A total of 118 febrile patients were recruited from November 16, 2021, to December 1, 2022. Of
354 these 84 (71.2%) were acute patients with onset of symptoms ranging from 0-5 days. A total of
355 42 patients (50.0 %) were DENV1 positive. We detected VEEV RNA (Ct range: 15-20) in five
356 patients (11.9%; 95% CI: 4.0 – 25.6) with suspected dengue infection, one of which was from a
357 fatal case in 2022. Details and results of disease surveillance are presented in Figure 3.
358

359 **Viral detection in mosquito pools**

360 A total of 1307 mosquitoes belonging to 35 species and 12 genera were collected in the
361 community of El Real de Santa Maria, Panama, during a period of five days in 2015 (table 3).
362 The most abundant mosquito species was *Coquilletidia venezualensis* (37.5%, n=490 of 1307)
363 and *Culex Melanoconion vomerifer* (34.4%, n=450 of 1307). Mosquito species, number of
364 individuals and pools are shown in Table 3. Of 150 mosquito pools, 3 *Cx. (Mel.) vomerifer*

365 mosquito pools tested positive for VEEV by rRT-PCR (Ct range:26-30). Two of these rRT-PCR
366 positive pools also yielded viral isolates.

367

368 **VEEV Subtype identification**

369 Three mosquito pools and 4 human samples (including one from a fatal case in 2022), that tested
370 positive with the new VEEV complex rRT-PCR were sequenced using a virus untargeted
371 approach (<https://wellcomeopenresearch.org/articles/6-241>). Twenty-fold genome coverage
372 ranged from 45% to 100% (Table 4). Percentage of genome identity with VEEV reference strain
373 ranged from 87.7% to 90.0% (Table 4), while identity with the Panamanian VEEV ID subtype
374 prototype strain 3880 ranged from 96 to 97% (Table 4). Maximum likelihood phylogenetic
375 analysis indicated that the new viral genomes cluster together with historical Panamanian VEEV
376 ID subtype strains within the Panama/Peru genotype (bootstrap statistical support =100; Figure
377 4). Percentage of genome identity with VEEV reference strain ranged from 45% to 100% (Table
378 4).

379

380 **Discussion**

381 The VEEV complex, MADV and EEEV viruses have been detected throughout the Americas
382 and may account for a significant proportion of non-dengue acute febrile illness (2, 3, 5, 9).

383 Although several assays have been developed for the molecular detection of VEEV subtypes and
384 VEEV complex (14–20), many are laborious and time-consuming based in multiple PCR rounds
385 or posterior genome sequencing that can be only implemented in laboratories with appropriate
386 facilities (14–20). Co-circulation and the potential for co-infection with these viruses further
387 complicates their detection, particularly when they present similar clinical presentations and

388 there is a lack of available and convenient methods for detection of VEEV complex viruses and
389 MADV (19). For example, VEEV subtype ID and MADV have both been identified in Panamá,
390 and co-circulation of VEEV and MADV was detected in the Darién province of Panamá along
391 the Colombian border (5–7). Typically, cases are often detected during the neurological phase of
392 the disease (5, 35). At this stage, the virus has been cleared from the serum and diagnosis relies
393 mostly on serological testing. Because alphaviruses can induce an IgM response that lasts up to 2
394 to 3 months, the detection of anti-VEEV or anti-MADV IgM alone could yield a misdiagnosis if
395 seroconversion is not observed (5, 35).

396 We developed new accurate VEEV complex singleplex and MADV/EEEV duplex rRT-PCRs for
397 the detection of viral RNA and real-time differentiation of clinical and mosquito samples. Using
398 these assays, we detected VEEV ID subtype and MADV in samples that had tested negative with
399 a reference RT-PCR (19). We were also able to identify an individual with a VEEV ID subtype -
400 MADV co-infection, highlighting another advantage of our VEEV complex and MADV/EEEV
401 rRT-PCRs over previous methods. Co-infection cases are epidemiologically significant and may
402 have clinical relevance if associated with more severe disease (5). Our newly developed rRT-
403 PCR assays can be rapidly incorporated into diagnostic algorithms in endemic regions. We show
404 that the currently developed rRT-PCR allowed us to detect VEEV ID subtype RNA in samples
405 collected from patients at least within the first 5 days of symptoms, whereas alphavirus IgM and
406 IgG antibody responses usually develop >5–7 days post symptom onset (36). Interestingly, three
407 patients with detectable VEEV complex RNA were also VEEV IgM and IgG-reactive,
408 suggesting that VEEV re-infections are possible, a finding with potential implications for
409 alphavirus vaccine development.

410 Our newly developed rRT-PCR allows the detection of the recently identified VEEV ID subtype
411 in acute infections. Our results of prospective disease surveillance in Panama indicate that 11.9%
412 of suspected dengue cases are VEEV ID subtype infections and provide evidence for overlapping
413 alphavirus circulation with other endemic arboviral infections such as dengue. Moreover, our
414 findings support previous evidence suggesting that VEEV complex infections represent 10 % of
415 the dengue burden in Latin American endemic countries(2). VEEV complex infections are
416 clinically undistinguished from endemic infections such as dengue (2), thus the VEEV complex
417 burden may be underestimated in dengue endemic regions.

418 VEEV ID subtype RNA was detected in three mosquito pools from the *Cx. (Mel.) vomerifer*
419 species trapped during the 2015 outbreak in El Real de Santamaria, Panama. Mosquitoes, from
420 the *Cx. (Mel.) vomerifer* have been previously incriminated as a vector for VEEV ID subtype in
421 Panama (2). Two of these mosquito pools yielded viral isolates. None of the original pan-
422 alphavirus convectional RT-PCRs were able to detect viral RNA in the mosquito pools. This
423 suggests that our newly designed rRT-PCR has an increased sensitivity to detect VEEV complex
424 RNA in mosquito vectors. No MADV nor EEEV infections were detected in mosquitoes by
425 either pan-alpha, rRT-PCR or isolation methods. The same pattern of lack of MADV isolation or
426 detection in mosquitoes was observed during previous outbreak investigations undertaken by our
427 group in Panama (37, 38). Interestingly, low MADV frequency of isolation was also observed
428 during extensive mosquito investigations undertaken during the 1940-60s in Panama by the
429 Gorgas Memorial Laboratory; in these occasions MADV was only isolated twice from *Cx. (Mel.)*
430 *taeniopus* in 1964 and 1973, respectively (39, 40). The low frequency of MADV detection or
431 isolation in Panama contrast with features observed in the endemic region of Iquitos, Peru, where
432 active circulation of MADV in the enzootic vector *Culex (Mel.) pedroi* is frequently detected(9,

433 41). Taken together, the early reports along with recent evidence suggest that mosquito vectors
434 in Panama may be infected with MADV at a lower frequency when compared with VEEV ID
435 subtype and even MADV in other endemic regions. The reasons for this variation in MADV and
436 VEEV ID subtype frequency of isolation or detection from mosquitoes collected in Panama
437 remain unclear and may include variation in vector competence or viral heterologous
438 competition or even enhanced VEEV ID subtype transmission by insect specific virus as has
439 been shown with dengue and Zika viruses (42).

440 Only a small number of human and mosquito samples were available to validate the assays.
441 However, prospective disease surveillance allowed us to obtain additional samples to further
442 validate our new assays. While previously developed methods relied on the validation of assays
443 using plasmids, viral isolates, or a few human sera samples (13–21), our assay validation with
444 human sera, mosquitos, and post-mortem tissue samples is more realistic and typical in reference
445 laboratories. Moreover, our approach failed to detect two samples that had previously tested
446 positive back in 2015 using standard alphavirus generic primers (19). Vina-Rodriguez et al.,
447 reported an rRT-PCR that was designed from an alignment of 33 VEEV sequences (21).
448 Development of this assay did not include other species that comprise the VEEV complex, and
449 clinical samples were not available for evaluation (21). Our assays were designed using a greater
450 number of complete genome sequences with confirmation *in silico* that the primers and probes
451 match contemporary alignments. Interestingly, a second round of the generic alphavirus RT-PCR
452 undertaken in 2017 with the same primers have also failed to reamplify the former positives.
453 Viral RNA degradation over time is a likely explanation of these false negative samples(43).
454 Untargeted metagenomic sequencing of complete and near-complete genome sequences
455 confirmed that the VEEV ID subtype was detected using the VEEV complex primers; this

456 subtype has been detected in central and eastern Panama regions (7). Further VEEV ID subtype
457 evolutionary analyses are currently being undertaken to investigate host or vector adaptations.
458 Taken together, these data demonstrate the potential of molecular and genomic approaches to
459 improve the detection of VEE complex, MADV and EEEV acute infections, even in long-time
460 storage samples.

461 Additional prospective testing is warranted to fully characterize the assays' clinical and
462 surveillance performance. An additional limitation of this study is that the design requires two
463 separate assays for three viruses as the optimal design targets for the VEEV complex and MADV
464 overlap in a highly conserved region. However, the two rRT-PCRs can be performed together on
465 a single run, however, which improves lab workflow, and the VEEV complex assay can be
466 multiplexed with rRT-PCRs for other neurotropic arboviruses such as West Nile and St. Louis
467 encephalitis viruses without a loss in performance (manuscript in preparation).

468 In conclusion, we describe new sensitive and specific VEEV complex, MADV and EEEV rRT-
469 PCRs that provide significant benefits over available molecular methods, allowing us to detect
470 VEEV-MADV co-infections and VEEV human infection in samples that were negative with
471 other techniques. Early acute samples that were negative with other techniques. Early acute
472 samples (≤ 3 days since onset of symptoms), with coincidental VEEV specific antibodies and
473 VEEV viral RNA suggest that VEEV re-infections are possible. In addition, our newly
474 developed method allowed us to detect VEEV active viral circulation in mosquitoes collected
475 during an alphavirus outbreak response. The implementation of then assays in regions of
476 endemicity may improve the identification and characterization of these neurotropic
477 alphaviruses.

478

479

480

481 **Acknowledgements**

482 We thank Xacdiel Rodriguez, Yelissa Rios, Yaneth Pittí, Oriel Lezcano and Eddier Rivera and
483 Mileika Santos for technical support with sample processing and mosquito classification and
484 Alberto Cumbreira for the map construction. We also thank Leyda Abrego for providing reagents
485 for the rRT-PCR and Milena Gomez, Thais M. Coletti, Esmenia Rocha, Geovana Maria Pererira,
486 Erika R. Manuli for technical support with metagenomic sequencing

487

488 **Funding Sources**

489 JPC is funded by the Clarendon Scholarship from University of Oxford and Lincoln-Kingsgate
490 Scholarship from Lincoln College, University of Oxford (grant number
491 SFF1920_CB2_MPLS_1293647). This work was supported by SENACYT, through the grants
492 number FID-16-201 and FID-2021-96 grant to JPC; the National Institute of Allergy and
493 Infectious Diseases, National Institutes of Health (grant K08AI110528 to JJW) and the National
494 Institute of Allergy and Infectious Diseases, National Institutes of Health (grant K08AI110528 to
495 JJW) and Centers for Research in Emerging Infectious Diseases (CREID) Coordinating
496 **Research on Emerging Arboviral Threats Encompassing the Neotropics (CREATE-NEO)**
497 1U01AI151807 grant awarded to NV/KAH by the National Institutes of Health (NIH); and by
498 the Medical Research Council □ São Paulo Research Foundation CADDE partnership award
499 (MR/S0195/1 and FAPESP18/14389 □ 0 to NRF) (<https://caddecentre.org>). CAD was supported
500 by the NIHR HPRU in Emerging and Zoonotic Infections, a partnership between PHE,

501 University of Oxford, University of Liverpool and Liverpool School of Tropical Medicine (grant
502 no. NIHR200907).

503 **References**

- 504 1. Navarro JC, Carrera JP, Liria J, Auguste AJ, Weaver SC. 2017. Alphaviruses in Latin
505 America and the introduction of chikungunya virus Human Virology in Latin America:
506 From Biology to Control.
- 507 2. Aguilar P v., Estrada-Franco JG, Navarro-Lopez R, Ferro C, Haddow AD, Weaver SC.
508 2011. Endemic Venezuelan equine encephalitis in the Americas: Hidden under the dengue
509 umbrella. *Future Virol* <https://doi.org/10.2217/fvl.11.50>.
- 510 3. Arrigo NC, Adams AP, Weaver SC. 2010. Evolutionary Patterns of Eastern Equine
511 Encephalitis Virus in North versus South America Suggest Ecological Differences and
512 Taxonomic Revision. *J Virol* <https://doi.org/10.1128/jvi.01586-09>.
- 513 4. Forshey BM, Guevara C, Laguna-Torres VA, Cespedes M, Vargas J, Gianella A, Vallejo
514 E, Madrid C, Aguayo N, Gotuzzo E, Suarez V, Morales AM, Beingolea L, Reyes N, Perez
515 J, Negrete M, Rocha C, Morrison AC, Russell KL, Blair PJ, Olson JG, Kochel TJ. 2010.
516 Arboviral etiologies of acute febrile illnesses in western south America, 2000-2007. *PLoS*
517 *Negl Trop Dis* 4.
- 518 5. Carrera J-P, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, Abadía I,
519 Castaño E, Sosa N, Báez C, Estripeaut D, Díaz Y, Beltrán D, Cisneros J, Cedeño HG,
520 Travassos da Rosa AP, Hernandez H, Martínez-Torres AO, Tesh RB, Weaver SC. 2013.
521 Eastern Equine Encephalitis in Latin America. *New England Journal of Medicine*
522 <https://doi.org/10.1056/nejmoa1212628>.
- 523 6. Carrera JP, Pittí Y, Molaes-Martínez JC, Casal E, Pereyra-Elias R, Saenz L, Guerrero I,
524 Galué J, Rodriguez-Alvarez F, Jackman C, Pascale JM, Armien B, Weaver SC, Donnelly
525 CA, Vittor AY. 2020. Clinical and serological findings of madariaga and venezuelan

- 526 equine encephalitis viral infections: A follow-up study 5 years after an outbreak in
527 Panama. *Open Forum Infect Dis* <https://doi.org/10.1093/ofid/ofaa359>.
- 528 7. Quiroz E, Aguilar P v., Cisneros J, Tesh RB, Weaver SC. 2009. Venezuelan equine
529 encephalitis in Panama: Fatal endemic disease and genetic diversity of etiologic viral
530 strains. *PLoS Negl Trop Dis* <https://doi.org/10.1371/journal.pntd.0000472>.
- 531 8. Corniou B, Ardoin P, Bartholomew C, Ince W, Massiah V. 1972. First isolation of a South
532 American strain of Eastern Equine virus from a case of encephalitis in Trinidad. *Trop*
533 *Geogr Med* 24.
- 534 9. Aguilar P v., Robich RM, Turell MJ, O'Guinn ML, Klein TA, Huaman A, Guevara C,
535 Rios Z, Tesh RB, Watts DM, Olson J, Weaver SC. 2007. Endemic eastern equine
536 encephalitis in the Amazon region of Peru. *American Journal of Tropical Medicine and*
537 *Hygiene* <https://doi.org/10.4269/ajtmh.2007.76.293>.
- 538 10. Vittor AY, Armien B, Gonzalez P, Carrera J-P, Dominguez C, Valderrama A, Glass GE,
539 Beltran D, Cisneros J, Wang E, Castillo A, Moreno B, Weaver SC. 2016. Epidemiology of
540 Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan Equine
541 Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien, Panama.
542 *PLoS Negl Trop Dis* 10.
- 543 11. Gil LHVG, Magalhaes T, Santos BSAS, Oliveira L v., Oliveira-Filho EF, Cunha JLR,
544 Fraiha ALS, Rocha BMM, Longo BC, Ecco R, Faria GC, Furtini R, Drumond SRM,
545 Maranhão RPA, Lobato ZIP, Guedes MIMC, Teixeira RBC, Costa EA. 2021. Active
546 circulation of madariaga virus, a member of the eastern equine encephalitis virus complex,
547 in northeast brazil. *Pathogens* 10.

- 548 12. Lednicky JA, White SK, Mavian CN, el Badry MA, Telisma T, Salemi M, O'Kech BA,
549 Beau De Rochars VM, Morris JG. 2019. Emergence of Madariaga virus as a cause of
550 acute febrile illness in children, Haiti, 2015-2016. *PLoS Negl Trop Dis*
551 <https://doi.org/10.1371/journal.pntd.0006972>.
- 552 13. Pfeffer M, Proebster B, Kinney RM, Kaaden OR. 1997. Genus-specific detection of
553 alphaviruses by a semi-nested reverse transcription-polymerase chain reaction. *American*
554 *Journal of Tropical Medicine and Hygiene* 57.
- 555 14. Brightwell G, Brown JM, Coates DM. 1998. Genetic targets for the detection and
556 identification of Venezuelan equine encephalitis viruses. *Arch Virol* 143.
- 557 15. Romeiro MF, de Souza WM, Tolardo AL, Vieira LC, Henriques DA, de Araujo J,
558 Siqueira CEH, Colombo TE, Aquino VH, da Fonseca BAL, de Moraes Bronzoni RV,
559 Nogueira ML, Durigon EL, Figueiredo LTM. 2016. A real-time RT-PCR for rapid
560 detection and quantification of mosquito-borne alphaviruses. *Arch Virol* 161.
- 561 16. Linssen B, Kinney RM, Aguilar P, Russell KL, Watts DM, Kaaden OR, Pfeffer M. 2000.
562 Development of reverse transcription-PCR assays specific for detection of equine
563 encephalitis viruses. *J Clin Microbiol* 38.
- 564 17. Wang E, Paessler S, Aguilar P v., Carrara AS, Ni K, Greene IP, Weaver SC. 2006.
565 Reverse transcription-PCR-enzyme-linked immunosorbent assay for rapid detection and
566 differentiation of alphavirus infections. *J Clin Microbiol* 44.
- 567 18. Pisano MB, Seco MPS, Ré VE, Farías AA, Contigiani MS, Tenorio A. 2012. Specific
568 detection of all members of the Venezuelan Equine Encephalitis complex: Development
569 of a RT-Nested PCR. *J Virol Methods* 186.

- 570 19. Sánchez-Seco MP, Rosario D, Quiroz E, Guzmán G, Tenorio A. 2001. A generic nested-
571 RT-PCR followed by sequencing for detection and identification of members of the
572 alphavirus genus. *J Virol Methods* [https://doi.org/10.1016/S0166-0934\(01\)00306-8](https://doi.org/10.1016/S0166-0934(01)00306-8).
- 573 20. Bronzoni RVM, Moreli ML, Cruz ACR, Figueiredo LTM. 2004. Multiplex nested PCR
574 for Brazilian Alphavirus diagnosis. *Trans R Soc Trop Med Hyg* 98.
- 575 21. Vina-Rodriguez A, Eiden M, Keller M, Hinrichs W, Groschup MH. 2016. A quantitative
576 real-time RT-PCR assay for the detection of venezuelan equine encephalitis virus utilizing
577 a universal alphavirus control RNA. *Biomed Res Int* 2016.
- 578 22. Benson DA, Cavanaugh M, Clark K, Karsch-Mizrachi I, Ostell J, Pruitt KD, Sayers EW.
579 2018. GenBank. *Nucleic Acids Res* <https://doi.org/10.1093/nar/gkx1094>.
- 580 23. Rojas A, Cardozo F, Cantero C, Stittleburg V, López S, Bernal C, Gimenez Acosta FE,
581 Mendoza L, Pinsky BA, de Guillén IA, Páez M, Waggoner J. 2019. Characterization of
582 dengue cases among patients with an acute illness, Central Department, Paraguay. *PeerJ*
583 2019.
- 584 24. Claudino-Sales V. 2019. Darien National Park, PanamaCoastal Research Library.
- 585 25. Santiago GA, Vázquez J, Courtney S, Matías KY, Andersen LE, Colón C, Butler AE,
586 Roulo R, Bowzard J, Villanueva JM, Muñoz-Jordan JL. 2018. Performance of the
587 Trioplex real-time RT-PCR assay for detection of Zika, dengue, and chikungunya viruses.
588 *Nat Commun* 9.
- 589 26. Sallum MAM, Forattini OP. 1996. Revision of the spissipes section of culex
590 (melanoconion) (diptera: Culicidae). *J Am Mosq Control Assoc*.
- 591 27. Johnson BW, Kosoy O, Wang E, Delorey M, Russell B, Bowen RA, Weaver SC. 2011.
592 Use of Sindbis/eastern equine encephalitis chimeric viruses in plaque reduction

- 593 neutralization tests for arboviral disease diagnostics. *Clinical and Vaccine Immunology*
594 18.
- 595 28. Claro IM, Ramundo MS, Coletti TM, da Silva CAM, Valenca IN, Candido DS, Sales
596 FCS, Manuli ER, de Jesus JG, de Paula A, Felix AC, Andrade P dos S, Pinho MC, Souza
597 WM, Amorim MR, Proenca-Modena JL, Kallas EG, Levi JE, Faria NR, Sabino EC,
598 Loman NJ, Quick J. 2021. Rapid viral metagenomics using SMART-9N amplification and
599 nanopore sequencing. *Wellcome Open Res* 6.
- 600 29. Li H. 2018. Minimap2: Pairwise alignment for nucleotide sequences. *Bioinformatics* 34.
- 601 30. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G,
602 Durbin R. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25.
- 603 31. Oxford Nanopore. 2022. GitHub Create statistic summary of an Oxford Nanopore read
604 dataset.
- 605 32. Milne I, Stephen G, Bayer M, Cock PJA, Pritchard L, Cardle L, Shawand PD, Marshall D.
606 2013. Using tablet for visual exploration of second-generation sequencing data. *Brief*
607 *Bioinform* 14.
- 608 33. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7:
609 Improvements in performance and usability. *Mol Biol Evol* 30.
- 610 34. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A,
611 Lanfear R, Teeling E. 2020. IQ-TREE 2: New Models and Efficient Methods for
612 Phylogenetic Inference in the Genomic Era. *Mol Biol Evol* 37.
- 613 35. Luciani K, Abadía I, Martínez-Torres AO, Cisneros J, Guerra I, García M, Estripeaut D,
614 Carrera JP. 2015. Case report: Madariaga virus infection associated with a case of acute
615 disseminated encephalomyelitis. *American Journal of Tropical Medicine and Hygiene* 92.

- 616 36. Torres-ruesta A, Chee RSL, Ng LFP. 2021. Insights into antibody-mediated alphavirus
617 immunity and vaccine development landscape. *Microorganisms*
618 <https://doi.org/10.3390/microorganisms9050899>.
- 619 37. Torres R, Samudio R, Carrera JP, Young J, Maârquez R, Hurtado L, Weaver S, Chaves
620 LF, Tesh R, Caâceres L. 2017. Enzootic mosquito vector species at equine encephalitis
621 transmission foci in the República de Panama. *PLoS One*
622 <https://doi.org/10.1371/journal.pone.0185491>.
- 623 38. Carrera J-P, Cucunuba ZM, Neira K, Lambert B, Pitti Y, Liscano J, Garzon JL, Beltran D,
624 Collado-Mariscal L, Saenz L, Sosa N, Rodriguez-Guzman LD, Gonzalez P, Lezcano
625 AGAG, Pereyra-Elias R, Valderrama A, Weaver SC, Vittor AY, Armien B, Pascale J-M,
626 Donnelly CA. 2020. Endemic and epidemic human alphavirus infections in eastern
627 Panama: An analysis of population-based cross-sectional surveys. *American Journal of*
628 *Tropical Medicine and Hygiene* 10:901462.
- 629 39. Dietz WH, Galindo P, Johnson KM. 1980. Eastern equine encephalomyelitis in Panama:
630 The epidemiology of the 1973 epizootic. *American Journal of Tropical Medicine and*
631 *Hygiene* <https://doi.org/10.4269/ajtmh.1980.29.133>.
- 632 40. Srihongse S, Galindo P. 1967. The isolation of eastern equine encephalitis virus from
633 *Culex (Melanoconion) taeniopus* Dyar and Knab in Panama. *Mosquito News* 27:74–76.
- 634 41. Turell MJ, O’Guinn ML, Jones JW, Sardelis MR, Dohm DJ, Watts DM, Fernandez R,
635 Travassos Da Rosa A, Guzman H, Tesh R, Rossi CA, Ludwig G v., Mangiafico JA,
636 Kondig J, Wasieloski LP, Pecor J, Zyzak M, Schoeler G, Mores CN, Calampa C, Lee JS,
637 Klein TA, 2006. Isolation of Viruses from Mosquitoes (Diptera: Culicidae) Collected in
638 the Amazon Basin Region of Peru. *J Med Entomol* 42:891–898.

- 639 42. Olmo RP, Todjro YMH, Aguiar ERGR, de Almeida JPP, Ferreira F v., Armache JN, de
640 Faria IJS, Ferreira AGA, Amadou SCG, Silva ATS, de Souza KPR, Vilela APP, Babarit
641 A, Tan CH, Diallo M, Gaye A, Paupy C, Obame-Nkoghe J, Visser TM, Koenraad CJM,
642 Wongsokarijo MA, Cruz ALC, Prieto MT, Parra MCP, Nogueira ML, Avelino-Silva V,
643 Mota RN, Borges MAZ, Drumond BP, Kroon EG, Recker M, Sedda L, Marois E, Imler
644 JL, Marques JT. 2023. Mosquito vector competence for dengue is modulated by insect-
645 specific viruses. *Nat Microbiol* 8:135–149.
- 646 43. Relova D, Rios L, Acevedo AM, Coronado L, Perera CL, Pérez LJ. 2018. Impact of RNA
647 degradation on viral diagnosis: An understated but essential step for the successful
648 establishment of a diagnosis network. *Vet Sci* 5.
- 649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673

674 **Tables**

675

676 **Table 1.** Primers and probes in the VEEV and MADV/EEEV rRT-PCRs.

677

Name	Sequence ^a	Concentration (nM) ^b	Location (5'-3') ^c	Sequences Fully Matching ^d
<i>VEEV</i>				
VEEV Forward 1	GAAAGTTCACGTT	200	44-67	156/159 (98)
	GAYATCGAGGA			
VEEV Forward 2	GAAGGTTTCACGTT	200		
	GAYATCGAGGA			
VEEV Reverse 1	GCTCTGGCRRTTAG	200	144-163	159/159 (100)
	CATGGTC			
VEEV Reverse 2	GCTCTAGCRRTTAG	200		
	CATGGTC			
VEEV Probe	5'-FAM-	400	112-134	158/159 (99)
	TTGAGGTAGAAGC HAAGCAGGTC- BHQ-1-3'			
<i>MADV/EEEV</i>				
ME Forward	GAGATAGAAGCM	400	121-141; 99-119	31/32 (97); 1/449 (100)
	ACGCAGGTC			
ME Reverse	TGYTTGGAATGCG	400	255-272; 233-250	32/32 (100); 9/449 (98)
	TGTGC			
MADV Probe	5'-FAM-	200	195-214	31/32 (97)
	CATCGAAAGCGAA GTGGACC-BHQ-1- 3'			
EEEV Probe	5'-CFO560-	400	176-198	6/449 (99)
	TGAGGGAGAAGT GGAYACAGACC-			

BHQ-1-3'

678

679 Abbreviations: BHQ, black hole quencher; CFO560, CAL Fluor Orange 560; FAM, Fluorescein

680 ^a probe sequences listed 5'-fluorophore-sequence-quencher-3'

681 ^b Concentration in the final reaction mixture

682 ^c Location in the following complete genome sequences: VEEV strain VEEV/Homo sapiens/GTM/69Z1/1969/IAB

683 (Accession number KC344505.2); MADV strain Homo sapiens/Haiti-1901/2016 (MH359233.1); EEEV strain

684 EEEV/Culiseta melanura/USA/SL13-0764-C/2013 (Accession number KX029319.1)

685 ^d Displayed as number of complete genome sequences without a mismatch in the primer/probe sequence over all

686 complete genome sequences aligned (%). Genomes downloaded 22 Sept 2021. Data shown for the combination of

687 forward and reverse VEEV primers.

Table 2. Characteristics and laboratory results of samples used for protocol validation patients and clinical samples and laboratory results. Acute samples selected from the 2015 and 2017 alphavirus outbreaks in Darien Province.

Code	Township	Age*	Sex	Symptoms onset	Days of symptoms	RT-PCR-Alpha (2015)	RT-PCR-Alpha (2021)	rRT-PCR-VEE	Ct values	IgM-VEEV	IgM-MADV	IgG-VEEV	IgG-MADV	PRNT-VEEV ϕ	PRNT-MADV ϕ
258384	El Real	0-9	M	Aug. 2015	0	pos	neg	pos	29.3	neg	neg	neg	neg	<1:20	<1:20
267738	Cemaco	0-9	M	July 2017	3	neg	neg	pos	37.8	pos	neg	neg	neg	<1:20	<1:20
267411	Tucuti	0-9	F	July 2017	5	neg	neg	neg	-	pos	neg	pos	pos	1:40	1:40
258380	El Real	0-9	F	Aug. 2015	1	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
267410	Yaviza	0-9	F	July 2017	2	neg	neg	neg	-	pos	neg	pos	neg	<1:20	<1:20
258657	Yaviza	10-19	M	Sept. 2015	0	pos	neg	pos	28	neg	neg	neg	neg	<1:20	<1:20
258535	Nicanor	20-29	F	Sept. 2015	2	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
258401	La Palma	20-29	M	Aug. 2015	2	pos	neg	pos	29	neg	neg	neg	neg	<1:20	<1:20
258395	Metetí	30-39	M	Aug. 2015	2	neg	neg	pos	37	pos	neg	neg	neg	<1:20	<1:20
258399	El Real	30-39	M	Aug. 2015	1	pos	neg	pos	26	neg	neg	neg	neg	<1:20	<1:20
258385	El Real	30-39	M	Aug. 2015	2	pos	neg	pos	37	neg	neg	neg	neg	<1:20	<1:20
258398	El Real	30-39	M	Aug. 2015	0	pos	neg	pos	27	neg	neg	pos	neg	<1:20	<1:20
258536	Metetí	30-39	F	Sept. 2015	2	pos	neg	neg	-	neg	neg	neg	neg	<1:20	<1:20
258386	El Real	30-39	M	Aug. 2015	5	pos	neg	pos	34	neg	neg	neg	neg	ND	ND
258379	El Real	≥40	F	Aug. 2015	2	pos	neg	pos	31	neg	neg	neg	neg	<1:20	<1:20

*Age categories in years

φ Base on PRNT-80

Abbreviations: Ct, cycle threshold; neg, negative; pos, positive, ND=not done.

Table 3. Mosquito species collected during the 2015 outbreak in El Real de Santa Maria, Panama.

Mosquitos species	N	(%)	# Pools	VEE-rRT-PCR Positive	MADV-rRT-PCR Positive	Viral solates
<i>Coquillettidia venezuelensis</i>	490	37.5	29	0	0	0
<i>Culex</i> (<i>Melanoconion</i>) <i>vomerifer</i>	450	34.4	27	3	0	2
<i>Culex</i> (<i>Melanoconion</i>) <i>pedroi</i>	32	2.4	4	0	0	0
<i>Aedes serratus</i>	31	2.4	7	0	0	0
<i>Aedes sp.</i>	30	2.3	5	0	0	0
<i>Culex</i> (<i>Melanoconion</i>) <i>sp.</i>	30	2.3	6	0	0	0
<i>Culex</i> (<i>Culex</i>) <i>interrogator</i>	27	2.1	5	0	0	0
<i>Anopheles trianulatus</i>	23	1.8	2	0	0	0
<i>Aedes eupoclamus</i>	14	1.1	4	0	0	0
<i>Culex</i> (<i>Culex</i>) <i>nigripalpus</i>	14	1.1	3	0	0	0
<i>Culex</i> (<i>Culex</i>) <i>sp.</i>	14	1.0	4	0	0	0
<i>Culex</i> (<i>Melanoconion</i>) <i>atratus</i>	14	1.0	1	0	0	0
<i>Culex</i> (<i>Melanoconion</i>) <i>adamesi</i>	13	1.0	3	0	0	0
Others*	125	9.6	50	0	0	0
Total	1307	100	150	3	0	2

Species <1% abundance are listed as Others.

Numbers of mosquito pools

Table 4. Metadata and sequencing statistics for selected VEEV complex RNA positive samples.

ID	Collection date	Location	Host species	%genome coverage 20X	% Nt Identity with genome reference^a	% Identity with strain 3880b
700677	2015	Darien	<i>Culex (Mel.) vomerifer</i>	100	89.8	92.1
700680	2015	Darien	<i>Culex (Mel.) vomerifer</i>	100	89.8	92.2
700732	2015	Darien	<i>Culex (Mel.) vomerifer</i>	100	90	92.3
258379	2015	Darien	<i>Human</i>	99.9	89.6	92
258398	2015	Darien	<i>Human</i>	70	88.7	90.7
258401	2015	Darien	<i>Human</i>	90.6	87.7	90
278716	2022	Darien	<i>Human</i>	45.98	88.1	90

^aGenbank accession no. NC_001449.1

^bPanamanian VEEV ID subtype prototype strain 3880, GenBank accession no. L00930.1
Nt=Nucleotide.

Figure legends

Figure 1. Map with the distribution of VEEV human cases in Darien province in 2015 and 2017 and Health centres in Panama and Darien Provinces. A. Distribution of VEEV cases used for protocol validation. Red dots represent the number of cases reported by locality. **B.** Distribution of Health centers used for prospective febrile surveillance in Panama and Darien provinces. Map was created with ArcGIS Desktop 10.6 using shapefiles from Esri. Data sources for the shapefiles include Esri, Garmin International Inc., US Central Intelligence Agency, and National Geographic Society (39).

Figure 2. VEE and MADV/EEEV rRT-PCR linearity and limit of detection. A)

Amplification curves across the linear range of the VEE complex rRT-PCR with ssDNA (gray curves, subtype IAB) and RNA (pink dotted curves, subtype IC). **B)** Linearity and limit of detection for VEE were evaluated with ssDNA from subtypes IAB (grey) and IV (purple) and RNA from subtype IC (pink). **(C-D)** Linearity and limit of detection for MADV © and EEEV (D) were evaluated using ssDNA. For each virus, ssDNA was tested in quadruplicate at 8.0, 6.0, 4.0, 2.0 and 1.0 log₁₀ copies/μL (labelled a-e, respectively). 10-fold dilutions of VEEV subtype IC RNA were tested in duplicate starting at the highest concentration available (5.0 log₁₀ copies/μL). All data points are displayed, including 2/4 MADV and EEEV replicates that did not yield cycle threshold (Ct) values and were excluded from the linear regressions.

Figure 3. Flowchart of patient recruitment, characteristics and RT-PCR results of febrile patients detected throughout disease surveillance. Febrile patients were recruited from November 16, 2021, to December 1, 2022, in ten health care centers of Panama and Darien provinces.

Figure 4. VEEV complex maximum likelihood phylogenetic tree. Maximum likelihood phylogenetic was estimated using 139 complete or near complete VEEV genomes. Publicly available Panamanian VEEV ID subtype strains are highlighted in grey (n=) and genomes generated in this study (n=7) are highlighted in red. Bootstrap statistical support are shown for selected nodes. NCBI GenBank accessions numbers for the new VEEV genomes are: XX-XX.

Figure 1. Map with the distribution of VEEV human cases in Darien province in 2015 and 2017 and Health centres in Panama and Darien Provinces.

medRxiv preprint doi: <https://doi.org/10.1101/2022.04.04.22271864>; this version posted February 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.





Figure 2. VEE and MADV/EEEV rRT-PCR linearity and limit of detection.





Figure 3. Flowchart of patient recruitment, characteristics and RT-PCR results of febrile patients detected throughout disease surveillance.



medRxiv preprint doi: <https://doi.org/10.1101/2022.04.04.22271864>; this version posted February 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

